文献速递泌尿生殖技术与安全PETCT

68Ga-PSMA-11 PET/CT 在新诊断前列腺癌中的诊断敏感度与观察者间一致性

68Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer: diagnostic sensitivity and interobserver agreement.
PubMed 文献 · Abdom Radiol (NY) · 2019-01-01

这项前瞻性研究纳入173例新诊断未治疗前列腺癌患者,均行68Ga-PSMA-11 PET/CT,以组织病理为参考标准。结果显示诊断敏感度为96%,28.6%患者分期发生显著改变(17.9%升期、10.7%降期),观察者间一致性视觉判读、SUVmax测量与肿瘤分期为k=0.63-0.89。作者认为该检查诊断敏感度高、可重复性好。

要点

  • 68Ga-PSMA-11 PET/CT 对新诊断前列腺癌的诊断敏感度为96%。
  • 该检查使28.6%患者分期改变:17.9%升期、10.7%降期。
  • 视觉判读、SUVmax测量与肿瘤分期的观察者间一致性为k=0.63-0.89。

核心结论

  • 68Ga-PSMA-11 PET/CT 是诊断和分期新诊断前列腺癌的有价值工具,诊断敏感度高(96%)且可重复性高。

研究设计与样本

  • 前瞻性研究,2017年1月至2018年8月纳入173例新诊断未治疗前列腺癌男性(平均年龄68±7.7岁,范围46-84岁)。
  • 所有患者行68Ga-PSMA-11 PET/CT检查,以组织病理为参考标准。
  • 对每例患者确定疾病分期、Gleason评分以及原发前列腺肿瘤和前列腺外转移灶的最大标准化摄取值(SUVmax)。

关键影像表现/征象

  • 173例中166例68Ga-PSMA-11 PET/CT判读为前列腺癌阳性:101例仅有原发前列腺肿瘤,2例仅有前列腺外转移灶,63例为原发灶与转移灶同时存在。

诊断标准与关键数值

  • 68Ga-PSMA-11 PET/CT 诊断前列腺癌的敏感度为96%。
  • 68Ga-PSMA-11 PET/CT 使28.6%患者分期发生显著改变,其中17.9%升期、10.7%降期。
  • 视觉图像判读、SUVmax测量和肿瘤分期的观察者间一致性为k=0.63-0.89,几乎为良好至完美。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To determine the diagnostic sensitivity and interobserver agreement of Gallium 68-prostate-specific membrane antigen positron emission tomography/computed tomography (68Ga-PSMA-11 PET/CT) imaging for diagnosis and staging of patients with newly diagnosed prostate cancer (PC).

MATERIALS AND METHODS: One hundred and seventy-three men (mean age, 68 ± 7.7 years; range 46-84 years) with newly diagnosed, untreated PC were enrolled in this prospective study between January 2017 and August 2018. All patients underwent a 68Ga-PSMA-11 PET/CT examination. For each patient, we determined the disease stage, the Gleason score, and the maximum standardized uptake value (SUVmax) for primary prostatic tumor and extraprostatic metastases. The diagnostic sensitivity and interobserver agreement of 68Ga-PSMA-11 PET/CT for diagnosis and staging of PC were established by histopathology as the reference standard.

RESULTS: 68Ga-PSMA-11 PET/CT examinations were interpreted as positive for PC in 166 of 173 patients (101 patients had primary prostatic tumor only, two patients had extraprostatic metastases only and 63 patients had combined lesions). The sensitivity of 68Ga-PSMA-11 PET/CT examination in the diagnosis of PC was 96%. 68Ga-PSMA-11 PET/CT produced a significant change of stage in 28.6% patients with an upstage in 17.9% patients and a downstage in 10.7% patients. The interobserver agreements were almost good to perfect (k = 0.63-0.89) for visual image interpretation, SUVmax measurement, and tumor staging.

CONCLUSION: 68Ga-PSMA-11 PET/CT is a valuable tool with high diagnostic sensitivity (96%) and high reproducibility for diagnosis and staging of patients with newly diagnosed PC.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Basha MAA, Hamed MAG, Hussein O, et al. 68Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer: diagnostic sensitivity and interobserver agreement. Abdom Radiol (NY). 2019. PMID: 30963182. doi:10.1007/s00261-019-02006-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。